Related documents, manuals and ebooks about What Is Persidis Disease
to identify novel therapies for any neglected Disease Aris Persidis, Ph.D., President, Biovista, Inc. Mechanism of Action (MoA) can be used to map any drug against any disease and any adverse event. A systematic effort to identify novel
than any other communicable disease except tuberculosis (Persidis, 2000). P. vivax infections account for more than half of the cases of malaria outside Africa and approximately 10% of the malaria in Africa. It is also prevalent in many regions of Asia and
New Life for Old Drugs Published on Drug Discovery & Development (http://www.dddmag.com) potential indications that may be of interest to the company,” says Aris Persidis,
Inherited Disease (Scriver CR, Beaudet A, Sly W and Valle D eds) 7th ed., pp 293–326, McGraw-Hill Book Company, New York. ... Persidis A (1998) The business of pharmacogenomics. Nat Biotechnol 16:209–210. Reddy CS and Hayes AW (1989) ...
Human Disease, Models of Immune Processes and Transgenic Tools. Data on mutant strains includes detailed information on ... Pasparakis M, Persidis A, Pfeffer K, Radbruch A, Rajewsky K, Ricciardi-Castagnoli P, Romagne F, Schneider P, Tocchini – Valentini G, Tschopp J, Van den Broek M ...
Group of parasites Examples Common name Clade Host Disease symptoms GI/livestock Haemonchus contortus Barber pole worm V Sheep and goat Anemia, diarrhea, lethargy, death ... (Persidis, 1999; Prasad et al., 2002; Moye-Rowley, 2003; Prasad and Kapoor, 2004; Sipos and Kuchler, 2006;
pathogeny of the disease and the role PDT plays therein. REFERENCES 1. Olivier S, Harissi-Dagher M, Sebag M. Photodynamic therapy for chronic serous detachment of the retinal pig-ment epithelium in a young patient. ... Persidis E, Conway MD, ...
By Dr Aris Persidis Drug Discovery World Spring 2011 9 Drug Development The benefits of ... systematic evaluation of any drug or mechanism of action against any disease or adverse event. Drug repositioning_Layout 1 16/03/2011 13:54 Page 9. of their originally-targeted indications, can lever-
Persidis, Biotechnology in a Snapshot, 18 NATURE BIOTECHNOLOGY IT2 (2000) (Industry T rends Supplement). ... disease group such as the Framingham heart study patients, or even the population of a Iceland. In fact, ...
Andreas Persidis BIOVISTA Klaus Rajewsky Center for Blood Research Inc. Jurg Tschopp University of Lausanne Glauco Tocchini-Valentini CNR Andreas Radbruch ... ¾Disease phenotype to gene function through disease sensitized mutagenesis screens (ENU, transposon, ...
Many people worldwide suffer from bone defects due to trauma or disease. About 5-10% of football injury-related bone fractures, in addition to bone tumor resection and massive ... Persidis, A.(1999). Tissue engineering. Nat Biotechnol, Vol. 17, pp.(508-510)
understanding the contribution of complex biological pathways to human pathophysiology and disease. In the post-genomic era, the concept ... A. Persidis, S. Deftereos, A. Persidis, Systems literature analysis, Pharmacogenomics 5 (2004) 943–947.
Most of these cases are diagnosed in the late stages of the disease where a combination of cost-effectiveness and affordable interventions is lacking. Other risk factors associated directly with breast cancer include hereditary, ... (Persidis, 1999). Given the
ing individualized medicine (Cohen, 1997; Persidis, 1998). Pharma-cogenomics, which relates genomic function to molecular pharmacol-ogy, promises to redefine basic notions in drug discovery and disease management. Some companies are devoting their efforts to establish-
396 Afr. J. Biotechnol. Table 1. Key milestones in the development of biotechnology. Year Development Reference 1877 Louis Pasteur and Joules F. Joubert first describe inhibition of bacterial growth Persidis, 1999
disease. Considering the characteristics of this study, we cannot state that PDT improves final VA or prevents long-term recurrences. ... Persidis E, Conway MD, et al. Ocular photodynamic therapy for serous macular detachment in the diffuse reti-
Disease Preg n acy/L tion Adapted from ICH E5, 1998: http://www.fda.gov/cder/guidance/2293fnl.pdf Extrinsic factors ... <Survey via Biovista; courtesy: Aris Persidis> 12 (Huang, S-M, Advisory committee, http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4248s1-index.htm)
Plasmodium falciparum, is considered an inflammatory disease. Objective: We determined P-glycoprotein expression at protein levels in human CM brain capillaries. ... Persidis A. Cancer multidrug resistance. Nat Biotechnol. 1999; 17:94-5. 3.
array of drug-like properties) there is a rationale for employing high quality (i.e. in vivo models of disease) forms of phenotypic screening in order to uncover otherwise unpredictable ... Dr. Persidis will illustrate the following critical thoughts regarding repositioning today:
large role on disease response? Ethical Considerations Will people with rare genetic profiles simply ... Persidis A. “Pharmacogenomics and diagnostics.” Nat Biotechnol. 1998 Aug;16(8):791-2. References 16) Housman D, Ledley FD. “Why pharmacogenomics?
the target (Persidis 1998, Sittampalam et al. 1997). ... ing for ion channels and comment on the opportunities for improvements ... diac disease states while retaining target selectivity and speciﬁc modes of action to minimize side effects.
disease for decades, but the field of proteomics offers a more global perspective. Because such analysis embraces ... PERSIDIS, A. (2001). Proteomics. Nat. Biotechnol, 18,Suppl, IT45–IT46. PETRICOIN, E.F., ARDEKANI, A.M., HITT, B.A., et al.
predisposition to disease and developing cures for the NEW HORIZONS Future Challenges of Pharmacogenomics in Clinical Practice V. Bansal, V. Kumar*, B. Medhi. ... Persidis A. Pharmacogenomics and diagnostics. Nature Biotechnology1998;16:791-92. 8.
Aris Persidis, Ph.D., President, Biovista, Inc. Sponsored by Drugs are very valuable assets with multiple revenue options. It is entirely pos- ... Disease System Biology Grant R. Zimmermann, Ph.D., Vice President, Discovery Sciences &
potential (Persidis 1999). Successful tissue engineering requires the coordi-nation of three elements: the ... (1999) Destructive periodontal disease in adults 30 years of age and older in the United States, 1988–1994. Journal of Periodontology
THE ANTIMALARIAL ACTIVITY OF THE CRUDE ORGANIC EXTRACTS OF FOUR COMMONLY USED NIGERIAN MEDICINAL PLANTS. ... The limited number of such drugs has led to increasing difficulties in the development of antimalarial drug policy and adequate disease management ... (Persidis, 2000).
Malaria is today a disease of poverty and undeveloped countries but it remains an important health problem globally. In the last decade, ... Persidis, A (2000). Malaria. Nature Biotechnology 18: 111-112. Phillipson, J.D (1991).
the possibility of disease transmission between the donor and ... Hazlehurst, 2004; Lysaght and Reyes, 2001; Persidis, 1999). A current major technical and engineering challenge is to provide suitable TE scaffolds (Grifﬁth and Naughton, 2002).
sate the loss of function in tissues of the human body which is due to disease, trauma or congenital defects. ... Persidis 2000). The primary goal of all approaches in tissue engineering is the restoration of function through the delivery of living elements which become integrated into the
disease management companies, advocacy or-ganizations, regulators, or the government. ... ARIS PERSIDIS isPr edn tofB v a pr iv ae l y h db oc ng m f s n ov elu sf rx itg da p h f ctsu i ng h rma o.F nf or mat, vsb .c 1.Payers and society are demanding more
odical understanding of a disease’s underlying mechanisms and helps monitoring areas where scientiﬁc advances are likely to create new therapeutic opportunities . ... 9 Persidis, A. (2011) Drug Repositioning: a union of patient interests,
• Member , Andreas Persidis, CEO, Biovista. HBio Members. BioAnalytica-GenoType S.A. Offering advanced molecular and cytogenetic analyses ... humanized disease animal models. Regulon S.A. Discovery and development of low-toxicity anticancer
identifying proteins that may correlate to various disease states.1 The rapid acceleration of research in the area of proteomics requires the development of new ... Persidis, A. Nat. Biotechnol. 1998, 16, 393-394. (2) Henzel, W. J.; Billeci, T. M.; Stults, J. T., Wong, S. C.; Grimley ...
injury or disease, and normal tissue repair. The understanding must come from ... Persidis, A., 2000. Tissue Engineering, Nature Biotechnology 18 Supplement 2000, IT56-58. 18. PEO (Professional Engineers Ontario) 2001. Final Report of the
Davidson's disease apical brush border GILBER: T AND RODRIGUEZ-BOULA 46N1 Demicolcemid ... PERSIDIS, LAY, MANOUSIS, BISHOP AND ELLA 61R 3 Replicase clusters formation and usag ien S-phase nuclei of human diploid fibroblasts: KILL BRIDGE, R et al 869
Andronis C, Sharma A, Virvilis V, Deftereos S, Persidis A: Literature mining, ontologies and information visualization for drug repurposing ... Liao JG, Chin K-V: Logistic regression for disease classification using microarray data: model selection in a large p and small n case ...
• Pharma/biotech companies or research institutions, developing inflammatory and autoimmune disease drugs The company also seeks • Partners with complementary services ... Andreas Persidis, PhD CEO Innovation, Unique advantages
Aromatic Hydrocarbon Metabolism by Rhodococcus sp. 124: Computational, Biochemical and Transcriptional Analysis By Jefferson A. Parker Submitted to the Department of Biology
... Persidis, A. Nat. Biotechnol. 1998, 16, 488–489. (2) Folch, A.; Toner, M. Annu. Rev. Biomed. ... estimated 35% of the disease burden within the seven major pharma markets. Notably, today there are no drugs available that can arrest
Research) and Andreas Persidis (BIOVISTA) who have acted as the review team and ... 10.5.1 Case report form development ... organ and disease to the population) by the disciplines of bioinformatics and medical
... disease mechanisms and genes involved at the effector. phase of arthritis. Arthritis Res Ther ... Schneider G, Kaljurand K, Hess M, Andronis C, Konstandi O, Persidis A. Mining of relations between proteins over biomedical scientific literature using a deep-linguistic approach. Artif ...
Ourania Konstanti, Andreas Persidis, and Aris Persidis 6.1. Introduction 137 6.2. Data Sources 138 6.2.1. Bioinformatics-Related Resources 139 ... Repositioning Drugs for Polycystic Kidney Disease: Perspectives from the Polycystic Kidney Disease Foundation 418 Jill Panetta and John McCall
Persidis. (2010) Dimebon Ameliorates Disease Severity in the MOG-induced Experimental Allergic Encephalomyelitis (EAE) Animal Model of Progressive Multiple Sclerosis (MS). American Neurological Association, 135th Annual Meeting, 12-15 September, San Fransisco
Nikos Tsioumas MD, Michail Basili MD, Efstratios Persidis MD, Konstantina Stamati MD, Maria Klonidou MD, Nikos Tsopelas MD. " ELPIS " GENERAL HOSPITAL DEPARTMENT OF OPHTHALMOLOGY ... to quantify the glaucomatous damage and to control the disease in time.
Prevention of pneumococcal disease in young children. Nurs Stand. 2001 Oct 3-9;16(3):42-4. PMID: 11977703 [PubMed - indexed for MEDLINE] 227: Bayat A. Science, medicine, and the future: Bioinformatics. BMJ. 2002 Apr 27;324(7344):1018-22. Review.
... (CH), Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. (DE), A. Persidis & SIA O.E. (GR), Instytut ... sparked the development of many new tools for today's biomedical researcher to use in finding the mechanism behind disease. While the goal is clear, the path ...
... treatment and surgery of rare disease; ... de Madrid UPM ESP CR 11 Fraunhofer-Gesellschaft zur Foerderung der angewandten Forschung FHG GER CR 12 A. Persidis & SIA O.E. BIOVISTA GRE CR 13 University of Crete UOC GRE CR 14 Unisersitaet Hannover UHANN GER CR 15 Instytut Chemii ...